JAK抑制剂治疗类风湿关节炎患者对带状疱疹亚单位疫苗的细胞免疫应答受损
本研究纳入46例接受JAK抑制剂治疗的类风湿关节炎患者和37名健康对照,接种两剂带状疱疹亚单位疫苗。结果显示患者CD19+细胞增殖显著增加,但CD4+、CD8+细胞增殖及TNFα、IFNγ产生无显著变化,且达到阳性疫苗应答的比例低于对照,提示T细胞应答受损。
要点
- JAK抑制剂治疗的RA患者对HZ/su疫苗的T细胞应答受损。
- 患者CD4+、CD8+细胞增殖及TNFα、IFNγ产生无显著增加。
- 建议在启动JAK抑制剂前接种带状疱疹疫苗。
核心结论
- 接受JAK抑制剂治疗的RA患者对带状疱疹亚单位疫苗的T细胞应答受损。
- 为确保满意的细胞免疫,RA患者应优先在启动JAK抑制剂治疗前接种带状疱疹疫苗。
研究设计与样本
- 研究纳入瑞典Skåne大学医院风湿科接受JAK抑制剂治疗的RA患者46例和健康对照37例,两组均接种两剂HZ/su疫苗。
- 在接种前和接种后约6周采集血样,用流式细胞术分析VZV gE特异性淋巴细胞增殖,用免疫分析法分析gE特异性TNFα和IFNγ产生。
主要发现
- 接种后,患者组(P=0.016)和对照组(P<0.001)的gE特异性CD19+细胞增殖均显著增加。
- 患者组接种后gE特异性CD4+或CD8+细胞增殖以及TNFα或IFNγ产生均无统计学显著差异。
- 达到阳性疫苗应答的患者比例在gE特异性CD4+、CD8+和CD19+细胞增殖以及gE特异性TNFα方面均低于对照组。
临床怎么用
- 对计划使用JAK抑制剂的RA患者,应考虑在治疗开始前完成带状疱疹疫苗接种以保障细胞免疫应答。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate cellular immune responses to the herpes zoster (HZ) subunit (HZ/su) vaccine in patients with rheumatoid arthritis (RA) treated with Janus kinase inhibitors (JAKis). METHODS: RA patients treated with JAKi (n = 46) at the Department of Rheumatology, Skåne University Hospital, Sweden, and healthy controls (n = 37) received two doses of the HZ/su vaccine. Blood samples were collected before and ∼6 weeks after vaccination. Varicella zoster virus (VZV) glycoprotein E (gE)-specific lymphocyte proliferation was analysed using flow cytometry. gE-specific production of tumour necrosis factor (TNF)α and IFNγ was analysed using an immunoassay. gE-specific responses were compared before and after vaccination within the groups (Wilcoxon signed-rank test), and between the patients and the controls (Mann-Whitney, ANCOVA). Proportions achieving a positive vaccine response were compared between the groups (Chi2 test). RESULTS: Following vaccination, gE-specific proliferation of CD19+ cells increased significantly in both the patients (P = 0.016) and the controls (P < 0.001). For patients, no statistically significant differences were seen after vaccination for gE-specific proliferation of CD4+ or CD8+ cells or production of TNFα or IFNγ. Lower proportions of patients than the controls achieved a positive vaccine response for gE-specific proliferation of CD4+, CD8+ and CD19+ cells and gE-specific TNFα. CONCLUSION: The lack of significant increases in both vaccine-specific proliferation of CD4+ and CD8+ cells and proinflammatory cytokines after vaccination indicate impaired T cell responses to the HZ/su vaccination in patients with RA treated with JAKi. These results suggest that to ensure satisfactory cellular immunity in patients with RA, vaccination against HZ should preferably be performed before the initiation of JAKi treatment. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; NCT03886038.
引用
- Källmark H, Gullstrand B, Kahn F, et al. Impaired cellular immune responses to herpes zoster subunit vaccine in patients with rheumatoid arthritis receiving Janus kinase inhibitors. Rheumatology (Oxford). 2026. PMID: 41330694. doi:10.1093/rheumatology/keaf626
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。